<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00722475</url>
  </required_header>
  <id_info>
    <org_study_id>IvIg for recurrent miscarriage</org_study_id>
    <secondary_id>EudraCT nr. 2008-001589-94</secondary_id>
    <nct_id>NCT00722475</nct_id>
  </id_info>
  <brief_title>Trial of the Efficacy of Intravenous Immunoglobulin for Treating Women With Unexplained Secondary Recurrent Miscarriage</brief_title>
  <official_title>A Randomized, Placebo-controlled, Double-blind Trial of Intravenous Immunoglobulin for Women With Unexplained Secondary Recurrent Miscarriage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Ministry of Science, Technology and Innovation, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators want to test whether infusions of intravenous immunoglobulin - a blood
      product known to modify immune responses - in early pregnancy will increase the chance of a
      subsequent live birth in women with three or more miscarriages after a birth and a total of
      at least four miscarriages. This will be done in a trial where 82 patients will be randomly
      allocated to infusions with intravenous immunoglobulin or placebo during pregnancy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The difference in the subsequent livebirth rate among patients with secondary recurrent miscarriage who, during the trial, receive intravenous immunoglobulin or placebo, respectively, without any exclusions (ITT analysis)</measure>
    <time_frame>August 2008 to June 2011</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The difference in the subsequent livebirth rate among women with secondary recurrent miscarriage who receive intravenous immunoglobulin or placebo, respectively, after relevant and predefined exclusions (PP analysis).</measure>
    <time_frame>August 2008 to June 2011</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Secondary Recurrent Miscarriage</condition>
  <arm_group>
    <arm_group_label>IvIg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Repeated infusions of intravenous immunoglobulin in early pregnancy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>infusion of human albumin CSL Behring 5%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous immunoglobulin</intervention_name>
    <description>Intravenous infusions, 25-35 g each time, 4th to 15th gestational week</description>
    <arm_group_label>IvIg</arm_group_label>
    <other_name>Intravenous immunoglobulin Privigen CSL Behring 100mg/ml</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Human albumin</intervention_name>
    <description>Repeated infusions of Human Albumin 5%, 250-350 ml between 4th and 15th gestational week</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>Human Albumin 5% CSL Behring</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  4 or more miscarriages before the end of gestational week 14 in patients with
             secondary recurrent miscarriages.

          -  At least three of these must be consecutive after the previous birth

          -  At least two of the miscarriages with the present partner.

        Exclusion Criteria:

          -  Age below 18 or above 41 years at conception

          -  Significant uterine anomalies detected by hysterosalpingography, hysteroscopy or
             hydrosonography.

          -  Significant chromosomal aberrations in the couple

          -  Menstrual cycle &lt; 23 or &gt; 35 days

          -  Presence of lupus anticoagulant or IgG anticardiolipin concentration &gt;= 40 GPL ku/l or
             plasma homocystein &gt;= 25 microg./l by repeated measurements at 8 weeks intervals

          -  Tests positive for HIV or tests indicating carriage of hepatitis B or C

          -  IgA deficiency

          -  Allergy to albumin, IvIg or one of the substances added to preserve the drugs.

          -  Presence of chronic disease, which necessitate permanent treatment with e.g.
             corticosteroids , non-steroidal antiinflammatory drugs, anticoagulation, simvastatin
             or imurel from the start of pregnancy.

          -  Less than 2 of the previous pregnancy losses documented by ultrasound or uterine
             curettage.

          -  Present pregnancy a result of donor insemination or egg donation.

          -  Planned administration of gestagens or estrogens from the beginning of pregnancy.

          -  3 or more previous IVF/ICSI/FER attempts resulting in chemical pregnancy/miscarriage.

          -  Previous participation in the trial.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ole B. Christiansen, MD, D.M.Sc.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fertility Clinic 4071, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Hutton B, Sharma R, Fergusson D, Tinmouth A, Hebert P, Jamieson J, Walker M. Use of intravenous immunoglobulin for treatment of recurrent miscarriage: a systematic review. BJOG. 2007 Feb;114(2):134-42. Epub 2006 Dec 12. Review.</citation>
    <PMID>17166218</PMID>
  </reference>
  <reference>
    <citation>Christiansen OB, Pedersen B, Rosgaard A, Husth M. A randomized, double-blind, placebo-controlled trial of intravenous immunoglobulin in the prevention of recurrent miscarriage: evidence for a therapeutic effect in women with secondary recurrent miscarriage. Hum Reprod. 2002 Mar;17(3):809-16.</citation>
    <PMID>11870141</PMID>
  </reference>
  <reference>
    <citation>Christiansen OB, Mathiesen O, Lauritsen JG, Grunnet N. Intravenous immunoglobulin treatment of women with multiple miscarriages. Hum Reprod. 1992 May;7(5):718-22.</citation>
    <PMID>1639992</PMID>
  </reference>
  <reference>
    <citation>Christiansen OB, Mathiesen O, Husth M, Rasmussen KL, Ingerslev HJ, Lauritsen JG, Grunnet N. Placebo-controlled trial of treatment of unexplained secondary recurrent spontaneous abortions and recurrent late spontaneous abortions with i.v. immunoglobulin. Hum Reprod. 1995 Oct;10(10):2690-5.</citation>
    <PMID>8567794</PMID>
  </reference>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2008</study_first_submitted>
  <study_first_submitted_qc>July 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2008</study_first_posted>
  <last_update_submitted>November 5, 2014</last_update_submitted>
  <last_update_submitted_qc>November 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Ole B Christiansen</investigator_full_name>
    <investigator_title>consultant</investigator_title>
  </responsible_party>
  <keyword>recurrent miscarriage</keyword>
  <keyword>immunology</keyword>
  <keyword>intravenous immunoglobulin</keyword>
  <keyword>miscarriage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Abortion, Spontaneous</mesh_term>
    <mesh_term>Abortion, Habitual</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

